(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
74
77
+
Continuation of Trastuzumab prolongs
median TTP in the GBG-26 study
++
+
+
+
+
5.6 a
a Median TTP in months
HR, hazard ratio
40
55
+
+
+
+
8.2 a
+
+
+
+ +
10 20 30
15
29
Time from 1st progression (months)
8
12
5
4
Trastuzumab + Capecitabine (n=78)
Capecitabine (n=78)
HR=0.69 (95% CI, 0.48-0.97, p=0.034)
3
3
2
1
+
1
1
40
1
1
von Minckwitz et al, J Clin Oncol 2009
+
+